A 52-year-old postmenopausal woman from Delhi presents with progressive abdominal distension and vague abdominal pain for 3 months. On examination, she has ascites and a palpable abdominal mass. CA-125 is 850 U/mL (normal <35). Imaging shows a large heterogeneous ovarian mass with peritoneal nodules and omental caking. Staging laparotomy reveals Stage IIIC disease with optimal cytoreduction (residual disease <1 cm). Which of the following is the most appropriate next step in management?

Explanation

## Management of Stage IIIC Optimally Cytoreduced Ovarian Cancer ### Clinical Scenario Analysis This patient has: - **Stage IIIC disease** (peritoneal involvement beyond pelvis + omental caking) - **Optimal cytoreduction** achieved (residual disease <1 cm) - **Good performance status** (able to tolerate surgery and chemotherapy) ### Standard Treatment Protocol **Key Point:** For optimally cytoreduced advanced ovarian cancer (Stage III–IV), the standard of care is **adjuvant chemotherapy** with paclitaxel 175 mg/m² and carboplatin (AUC 5–6) for 6 cycles, given intravenously every 3 weeks [cite:GOG-111, ICON-3 trials]. **High-Yield:** Neoadjuvant chemotherapy (NACT) is reserved for **suboptimally cytoreduced** disease or **medically unfit** patients. Since this patient achieved optimal cytoreduction at primary surgery, adjuvant chemotherapy is the standard approach. ### Why Adjuvant (Not Neoadjuvant)? | Approach | Indication | Timing | |----------|-----------|--------| | **Adjuvant** | Optimal cytoreduction at primary surgery | After surgery, 6 cycles | | **Neoadjuvant** | Suboptimal cytoreduction expected OR unfit for primary surgery | Before interval debulking | **Clinical Pearl:** The EORTC-55971 and CHORUS trials showed that NACT followed by interval debulking is equivalent to primary debulking + adjuvant therapy only when primary optimal cytoreduction cannot be achieved. Since this patient already has optimal disease, adjuvant chemotherapy is superior. ### Chemotherapy Regimen Details - **Paclitaxel:** 175 mg/m² IV over 3 hours - **Carboplatin:** AUC 5–6 IV - **Frequency:** Every 3 weeks × 6 cycles - **Duration:** ~18 weeks - **Response rate:** 60–70% in optimally cytoreduced Stage III disease ### Prognostic Factors in This Case - ✓ Optimal cytoreduction (residual <1 cm) — **favorable** - ✓ Stage IIIC (not Stage IV) — **relatively favorable** - ✗ Elevated CA-125 (850) — **unfavorable** - ✗ Large tumor burden at presentation — **unfavorable** **Mnemonic: OPTIMAL CYTO** — **O**ptimal residual disease <1 cm → **A**djuvant chemotherapy; **S**uboptimal residual >1 cm → **N**eoadjuvant chemotherapy. ### 5-Year Survival Outcomes - Optimally cytoreduced Stage IIIC + adjuvant chemotherapy: ~40–50% - Suboptimally cytoreduced Stage IIIC: ~20–30%